[en] INTRODUCTION: Among allergic rhinitis (AR) symptoms, nasal obstruction particularly affects the quality of life. Antihistamines and intranasal corticosteroids are the most frequently prescribed symptomatic drugs, but their efficacy is often incomplete. Essential oils (EO) have shown an anti-inflammatory effect and potential in treating patients with AR. The aim of this study was to evaluate the effectiveness of a hypertonic EO-based nasal spray on perennial AR (PAR) symptoms. METHODS: This prospective, open-label, non-randomized, multicentric trial included 43 patients with PAR sensitized to mites, not controlled for more than a year. All were treated with Puressentiel® Respiratory-Decongestant Nasal Spray for 30 days. Their usual treatment remained unchanged during the study period. Before and after treatment, each participant filled out a rhinitis questionnaire, the Allergic Rhinitis Control Test (ARCT). A nasal inspiratory peak flow (NIPF) was performed. RESULTS: The mean ARCT was 16.4 and 20.5 at D0 and D30, respectively (p < 0.001); the mean increase between D0 and D30 was 4.1 (p < 0.001). The proportion of patients with controlled rhinitis after 30 days of treatment was 69.8 versus 14% before treatment (p < 0.001). The mean NIPF was 86.5 L/min and 105.1 L/min at D0 and D30, respectively (p < 0.001); the mean increase between D0 and D30 was 18.5 L/min. CONCLUSION: A hypertonic EO-based nasal spray could be a new and natural option in the management of PAR. It could also be used as an add-on therapy when nasal symptoms are not fully controlled.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Caimmi, Davide
Neukirch, Catherine
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Malard, Olivier
Thabut, Gabriel
Demoly, Pascal
Language :
English
Title :
Effect of the Use of Intranasal Spray of Essential Oils in Patients with Perennial Allergic Rhinitis: A Prospective Study.
Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006 Jan; 117(1): 158-62.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA)2008 update (in collaboration with the world health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr; 63(Suppl 86): 8-160.
Demoly P, Allaert FA, Lecasble M. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy. 2002 Jun; 57(6): 546-54.
Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol. 2010 Jan; 104(1): 13-29.
Yanez A, Rodrigo GI. Intranasal corticosteroides versus topical H1 receptor antagonist for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002 Nov; 89(5): 479-84.
Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2002 Jun; 109(6): 949-55.
May JR, Dolen WK. Evaluation of intranasal corticosteroid sensory attributes and patient preference for fluticasone furoate for the treatment of allergic rhinitis. Clin Ther. 2019 Aug; 41(8): 1589-96.
Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998 Dec; 317(7173): 1624-9.
El W, Harris WC, Babcock CM, Alexander BH, Riley CA, McCoul ED. Epistaxis risk associated with intranasal corticosteroids sprays: a systemic review and meta-analysis. Otolaryngol Head Neck Surg. 2019 Jul; 161(1): 18-27.
Qiu J, Grine K. Complementary and alternative treatment for allergic conditions. Prim Care. 2016 Sep; 43(3): 519-26.
Kem J, Bielory L. Complementary and alternative therapy (CAM) in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2014 Dec; 14(12): 479.
Surda P, Fokkens WJ. Novel, alternative, and controversial therapies of rhinitis. Immunol Allergy Clin North Am. 2016 May; 36(2): 401-23.
De Cassia da Silveira e Sa R, Andrade LN, de Sousa DP. A review on anti-inflammatory activity of monoterpenes. Molecules. 2013 Jan; 18(1): 1227-54.
Ueno-Lio T, Shibakura M, Yokota K, Aoe M, Hyoda T, Shinoata R, et al. Lavender essential oil inhalation suppresses allergic inflammation and mucus cell hyperplasia in a murine model of asthma. Life Sci. 2014 Jul; 108(2): 109-15.
Choi Y, Park K. Effect of inhalation of aromatherapy oil with perennial allergic rhinitis: a randomized controlled trial. Evid Based Complement Alternat Med. 2016 Mar; 2016: 2103616.
Demoly P, Jankowski R, Chassany O, Bessah Y, Allaert FA. Validation of a self-questionnaire for assessing the control of allergic rhinitis. Clin Exp Allergy. 2011 Jun; 41(6): 860-8.
Ottaviano G, Fokkens WJ. Measurements of nasal airflow and patency: a critical review with emphasis on the use of peak nasal inspiratory flow in daily practice. Allergy. 2016 Feb; 71(2): 162-74.
Ryden O, Andersson B, Andersson M. Disease perception and social behavior in persistent rhinitis: a comparison between patients allergic and nonallergic rhinitis. Allergy. 2004 Apr; 59(4): 461-4.
Braniuk JN. Subjective nasal fullness and objective congestion. Proc Am Thorac Soc. 2011 Mar; 8(1): 62-9.
Panagou P, Loukides S, Tsipra S, Syrigou K, Anastasakis C, Kalogeropoulos N. Evaluation of nasal patency: comparison of patients and clinician assessments with rhinomanometry. Acta Otolaryngol. 1998 Nov; 118(6): 847-51.
Morrissey MS, Alun-Jones T, Hill J. The relationship of peak inspiratory airflow to subjective airflow in the nose. Clin Otolaryngol Allied Sci. 1990 Oct; 15(5): 447-51.
Juergens UR, Dethlefsen U, Steinkamp G, Gillissen R, Repges R, Vetter H. Anti-inflammatory activity of 1.8 cineol in bronchial asthma: a double-blind placebo controlled trial. Respir Med. 2003 Mar; 97(3): 250-6.
Bastos PD, Gomes AS, Lima FJB, Brito TS, Soares PM, Pinho JP, et al. Inhaled 1.8 cineole reduces inflammatory parameters in airways of ovalbumin-challenged guinea pigs. Basic Clin Pharmacol Toxicol. 2011 Jan; 108(1): 34-9.
Head K, Snidvongs K, Glew S, Scadding G, Schilder AG, Philpott C, et al. Saline irrigation for allergic rhinitis. Cochrane Database Syst Rev. 2018 Jun; 6(6): CD012597.
Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol. 1996 Feb; 97(2): 617-26.
